Compass Therapeutics (CMPX) investor relations material

Key program updates and clinical progress

• Four clinical-stage oncology drugs highlighted, with lead asset tovecimig advancing toward FDA discussions and potential BLA filing later this year.

• Tovecimig demonstrated significant efficacy in a phase II/III BTC trial, tripling response rates and improving PFS, with a median OS of 9.9 months for treated patients.

• CTX-471, a CD137 agonist, identified NCAM as a biomarker and will enter a phase II basket study for NCAM-positive tumors in the coming quarter.

• CTX-8371, a PD-1/PD-L1 bispecific, showed durable responses in post-checkpoint patients across multiple tumor types, with further data expected from ongoing cohort expansions.

• CTX-10726, a PD-1 VEGF-A bispecific, is in phase I with dose escalation data anticipated by year-end, targeting indications with established checkpoint and angiogenesis therapy efficacy.

Financial and operational outlook

• Ended Q1 with $195 million in cash, providing runway into 2028 and covering all ongoing clinical trials.

• Commercial launch preparations have begun, though current cash is not expected to fully fund the company to profitability or cover all launch costs.

Regulatory and strategic plans

• Tovecimig is on fast track with anticipated priority review; PDUFA date could be in the second half of 2027 if BLA is filed and accepted.

• FDA and key opinion leaders are expected to understand the confounding effects of crossover in the BTC trial, with primary and secondary endpoints met.

• Plans to expand tovecimig into additional solid tumor indications, starting with those where paclitaxel is standard, such as gastric and ovarian cancers.